389 related articles for article (PubMed ID: 30188734)
1. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
[TBL] [Abstract][Full Text] [Related]
2. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
3. Crystal Structures of Neurotrophin Receptors Kinase Domain.
Bertrand T
Vitam Horm; 2017; 104():1-18. PubMed ID: 28215291
[TBL] [Abstract][Full Text] [Related]
4. Trk kinase inhibitors as new treatments for cancer and pain.
Wang T; Yu D; Lamb ML
Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
[TBL] [Abstract][Full Text] [Related]
5. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
[TBL] [Abstract][Full Text] [Related]
6. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
[TBL] [Abstract][Full Text] [Related]
8. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
9. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
[TBL] [Abstract][Full Text] [Related]
10. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
[TBL] [Abstract][Full Text] [Related]
12. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition.
Bertrand T; Kothe M; Liu J; Dupuy A; Rak A; Berne PF; Davis S; Gladysheva T; Valtre C; Crenne JY; Mathieu M
J Mol Biol; 2012 Oct; 423(3):439-53. PubMed ID: 22902478
[TBL] [Abstract][Full Text] [Related]
13. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
14. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
[No Abstract] [Full Text] [Related]
15. [Back from ASCO 2019: Advances on NTRK inhibitors in childhood tumors].
Doz F
Bull Cancer; 2019; 106(7-8):615-616. PubMed ID: 31272686
[No Abstract] [Full Text] [Related]
16. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract][Full Text] [Related]
17. Loxo TRK inhibitor data wows oncologists.
Dolgin E
Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
[No Abstract] [Full Text] [Related]
18. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains.
Zaccaro MC; Ivanisevic L; Perez P; Meakin SO; Saragovi HU
J Biol Chem; 2001 Aug; 276(33):31023-9. PubMed ID: 11425862
[TBL] [Abstract][Full Text] [Related]
19. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review.
Panchal I; Tripathi RKP; Parmar K; Yadav MR
Curr Top Med Chem; 2024; 24(1):3-30. PubMed ID: 38058091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]